4-(羟基亚氨基)哌啶-1-羧酸叔丁酯 | 150008-24-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(羟基亚氨基)哌啶-1-羧酸叔丁酯
• 中文别名: 1-Boc-4-(羟基亚氨基)哌啶；N-BOC-4-(羟基亚氨基)哌啶
• 英文名称: tert-butyl 4-(hydroxyimino)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-hydroxyiminopiperidine-1-carboxylate
• CAS: 150008-24-5
• 化学式: C₁₀H₁₈N₂O₃
• 分子量: 214.265
• InChiKey: LDLQTMSUZKHEHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 包装等级：
  II
• 危险类别：
  4.1
• 危险性防范说明：
  P280,P210,P240,P264,P270,P301+P310,P330,P370+P378,P403+P233,P405,P501
• 危险品运输编号：
  1325
• 危险性描述：
  H228,H302,H317,H319,H341,H351
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-(羟基亚氨基)哌啶-1-羧酸叔丁酯 在 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 30.0h， 生成 1-(piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia

  摘要：

  1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an intraperitoneal glucose tolerance test. AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats. These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the observed pharmacology in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.042
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 吡啶 、 盐酸羟胺 作用下， 反应 2.0h， 以21.4 g的产率得到4-(羟基亚氨基)哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  通过 P(III)/P(V)═O 催化剂的空间设计实现硝基烷烃和硼酸的还原性 C-N 交叉偶联

  摘要：

  报道了硝基烷烃与芳基硼酸和酯的有机磷催化的 C-N 键形成还原偶联。该方法对硝基/硼酸底物对显示出优异的化学选择性，允许合成富含功能化的N -（杂）芳基胺。鉴定能够在 P(III)/P(V)=O 氧化还原歧管中进行有效偶联的空间还原磷杂环丁烷催化剂是实现发展的关键。结合实验动力学和计算机制研究表明，空间还原的催化剂影响后限速步骤，使 C-N 偶联事件优先于有害的旁路。

  DOI：

  10.1021/jacs.2c01487

文献信息

• Chemodivergent Synthesis of Oxazoles and Oxime Ethers Initiated by Selective C–N/C–O Formation of Oximes and Diazo Esters
  作者：Zhenjie Qi、Shaozhong Wang

  DOI：10.1021/acs.orglett.1c03252

  日期：2021.11.5

  Chemodivergent reactions of oximes and diazo esters involving Rh-catalyzed [3+2] annulation and photodriven O–H insertion have been developed to generate oxazoles and oxime ethers. A range of aldehyde and ketone oximes reacted with α-diazocarbonyl compounds in a controllable manner in which functional groups, including ketone, ester, amide, ether, thiol ether, silane, alkene, allene, and alkyne groups

  已经开发了涉及 Rh 催化的 [3+2] 环化和光驱动 O-H 插入的肟和重氮酯的化学发散反应，以生成恶唑和肟醚。一系列醛和酮肟以可控方式与 α-重氮羰基化合物反应，其中包括酮、酯、酰胺、醚、硫醇醚、硅烷、烯烃、丙二烯和炔基在内的官能团具有良好的耐受性。
• [EN] 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA 3-PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE ET LEURS UTILISATIONS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2017156177A1

  公开（公告）日：2017-09-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Chytil Milan

  公开号：US20100204214A1

  公开（公告）日：2010-08-12

  Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了融合咪唑基化合物，其合成方法以及使用方法。本文提供的化合物对于治疗、预防和/或管理各种疾病，如神经系统疾病和代谢性疾病，具有用处。本文提供的化合物抑制组胺H3受体的活性，并调节各种神经递质的释放，如组胺、乙酰胆碱、去甲肾上腺素和多巴胺（例如在突触处）。本文还提供了含有这些化合物的药物配方及其使用方法。
• An efficient catalytic method for the Beckmann rearrangement of ketoximes to amides and aldoximes to nitriles mediated by propylphosphonic anhydride (T3P®)
  作者：John Kallikat Augustine、Rajesha Kumar、Agnes Bombrun、Ashis Baran Mandal

  DOI：10.1016/j.tetlet.2010.12.090

  日期：2011.3

  An efficient method for the Beckmann rearrangement of ketoximes to amides mediated by a catalytic amount (15 mol %) of propylphosphonic anhydride (T3P®) is described. Aldoximes underwent second order Beckmann rearrangement to provide the corresponding nitriles in excellent yields on reacting with T3P (15 mol %) at room temperature. The main advantages of this environmentally friendly protocol include

  描述了一种由催化量（15摩尔％）的丙基膦酸酐介导的将酮肟的贝克曼重排成酰胺的有效方法。Aldoximes在室温下与T3P（15 mol％）反应后，进行了二阶Beckmann重排，从而以优异的产率提供了相应的腈。这种环境友好协议的主要优点包括程序简单，尤其是产品隔离容易。
• [EN] NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)<br/>[FR] NOUVEAUX INDOLE-2-CARBOXAMIDES ACTIFS CONTRE LE VIRUS DE L'HÉPATITE B (VHB)
  申请人：AICURIS GMBH & CO KG

  公开号：WO2020221826A1

  公开（公告）日：2020-11-05

  The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

  本发明一般涉及新型抗病毒药剂。具体地，本发明涉及能够抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰HBV复制周期功能的化合物，包括这种化合物的组合物，抑制HBV病毒复制的方法，治疗或预防HBV感染的方法，以及制备这些化合物的工艺和中间体。